Article Text

Download PDFPDF
Adjuvant Chemotherapy for Endometrial Cancer: Unproven
  1. Carien L. Creutzberg, MD, PhD
  1. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  1. Address correspondence and reprint requests to Carien L. Creutzberg, MD, PhD, Department of Clinical Oncology, K1-P, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: c.l.creutzberg{at}


High-risk endometrial cancer (EC), only 15% of all EC, mainly affects elderly women, often with significant comorbid diseases. Because patients with high-risk EC are at increased risk of distant metastases and EC death, the use of adjuvant chemotherapy has been investigated in several trials. Trials comparing radiotherapy and chemotherapy have not shown survival difference. A first trial comparing combinations of chemotherapy and radiotherapy with radiotherapy alone suggested progression-free survival benefit. Toxicity and quality of life data are lacking. The role of adjuvant chemotherapy for endometrial carcinoma remains unproven. High-risk EC remains the challenge for further research.

  • Endometrial cancer
  • Chemotherapy
  • Radiation therapy
  • Randomized trials

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.